Call for Abstract
Scientific Program
7th International Conference on Clinical Trials, will be organized around the theme “An Insight into Innovative Approaches in Global Clinical Research and Clinical Trials”
Clinical Trials 2018 is comprised of 20 tracks and 157 sessions designed to offer comprehensive sessions that address current issues in Clinical Trials 2018.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
- Track 1-1Clinical research in academic level
- Track 1-2Trends & perspectives in clinical research
- Track 1-3Preclinical research considerations
- Track 1-4Informed consent for trials
- Track 1-5Real world clinical trial strategies and results
- Track 1-6Pharma’s role in Bridging clinical research and health care
- Track 1-7Community outreach and education in clinical trials
- Track 1-8Perils and Pitfalls of miscommunication in research
- Track 1-9Misconducts of clinical trials
- Track 1-10Meetings with the FDA—Why, When and How
- Track 1-11FDA conduct of clinical investigator inspections
- Track 1-12Trials on Biologics and biosimilars
- Track 1-13Brexit’s Impact on clinical research
- Track 2-1Challenges in drug discovery & development
- Track 2-2Novel technologies in drug discovery
- Track 2-3Technologies in novel drug delivery systems
- Track 2-4Drug discovery in preclinical research
- Track 2-5Scientific formulation advancements in practice
- Track 2-6Why formulation and delivery strategies fail
- Track 2-7Experimental and computational approaches
- Track 3-1Early clinical development: Operational strategies
- Track 3-2Transforming clinical development
- Track 3-3Streamlining R&D clinical trials operations
- Track 3-4Translation of clinical trial documents – challenges, options and solution
- Track 3-5Clinical trial project management platforms
- Track 3-6Setting & managing priorities in a clinical project schedule
- Track 3-7Risk-Based monitoring
- Track 3-8Integrating quality into clinical trials
- Track 3-9Managing risk with contracts: Informed consent, Subject injury, Insurance & Indemnification
- Track 3-10Misconduct and fraud in clinical trials
- Track 3-11Good clinical practice and inspection readiness
- Track 4-1Strategic enrollment planning
- Track 4-2Innovative approaches to patient recruitment & retention
- Track 4-3data-driven recruitment and forecasting
- Track 4-4Incorporating data and patient insights into enrollment planning
- Track 4-5Reaching patients and improving recruitment operations using existing and/or innovative tools
- Track 4-6Harnessing the power of digital and social media to drive patient recruitment
- Track 5-1Creating truly patient centric trials
- Track 5-2Patient centric approaches to clinical trials
- Track 5-3Patient perspective on research and health care
- Track 5-4Creating patient centric trials using disruptive approaches to overcome barriers
- Track 5-5Patient involvement in developing clinical trials
- Track 5-6Understanding the future of patient engagement in clinical trials
- Track 6-1Design and end points of clinical trials
- Track 6-2Trial design: Formulation development, manufacturing and analytical testing
- Track 6-3Observational study designs
- Track 6-4Experimental study designs
- Track 6-5Randomized trial model
- Track 6-6Adaptive trial model
- Track 6-7Randomized placebo- controlled trials
- Track 6-8Maximizing trial success through Patient–Oriented study designs
- Track 7-1Challenges in conducting oncology trials
- Track 7-2Personalized cancer medicine
- Track 7-3Cancer biomarkers
- Track 7-4Feasibility and site selection in competitive immuno-oncology trials
- Track 7-5Studies on new HIV medicines
- Track 7-6Studies on infections related to HIV
- Track 7-7Trials on vaccines to prevent or treat HIV
- Track 7-8Benefits and possible risks of participating in HIV/AIDS clinical trial
- Track 7-9Benefits and risks of participating in cancer trials
- Track 8-1Clinical trials for diabetes and cardiovascular diseases
- Track 8-2Clinical trials for Alzheimer’s
- Track 8-3Trials on pulmonary/respiratory diseases
- Track 8-4Clinical trials for rare diseases: Challenges and opportunities
- Track 8-5Research and Trials on behaviors, mental, eating and sleeping disorders
- Track 8-6Research and studies on wounds and injuries
- Track 8-7Studies on parasitic, viral, bacterial and fungal diseases
- Track 9-1Rise of imaging in clinical trials
- Track 9-2Medical imaging modalities
- Track 9-3Considerations regarding the use of imaging in trials
- Track 9-4Technology solutions to streamline imaging in clinical studies
- Track 9-5Imaging as a biomarker
- Track 9-6Standardization of imaging protocols
- Track 10-1Big data for clinical trials
- Track 10-2Impact of real world data
- Track 10-3Clinical data strategy and analytics
- Track 10-4Data types and data processing techniques
- Track 10-5Data & Tech driven clinical trials
- Track 10-6Integrated technology platforms
- Track 10-7SAS programming in data analysis
- Track 10-8Electronic data capturing systems
- Track 10-9CRF/eCRF design and development
- Track 10-10Data visualization & Analytics techniques for clinical trial insights
- Track 10-11Digitalization of clinical trials
- Track 10-12Artificial intelligence in clinical research
- Track 11-1Innovations in clinical technologies
- Track 11-2Disruptive technologies for data and trial management
- Track 11-3Sensors, wearables and digital biomarkers in clinical trials
- Track 11-4Remote trials and digital technology
- Track 11-5Mobile technologies in clinical trials
- Track 11-6How technology can enable Patient-Centric clinical research
- Track 11-7Global needs for mobile health and potential technologies
- Track 12-1Challenges and opportunities of Sponsors and CROs
- Track 12-2Hidden costs for sites and sponsors
- Track 12-3CRO selection and management
- Track 12-4Financial aspects of clinical trials
- Track 12-5CRO perspective on bridging clinical trial processes to Real-World health care
- Track 12-6Globalization & Outsourcing
- Track 12-7Outsourcing trends & strategies
- Track 12-8Mastering an outsourcing strategy
- Track 12-9Lean outsourcing models for clinical trials
- Track 12-10Understanding the outsourcing function
- Track 12-11Constructing your contract for maximum benefit
- Track 12-12Strategic and tactical clinical outsourcing
- Track 13-1Protocol development, site selection, feasibility and management
- Track 13-2Data-driven feasibility, country selection, and site identification
- Track 13-3Develop a technology road map for your research site
- Track 13-4Site management innovation
- Track 13-5Modernizing your Site
- Track 13-6Marketing & Business development for sites
- Track 13-7Financial management of research sites
- Track 13-8Regulatory inspections of research sites
- Track 13-9Strategies to validate the siteless trial
- Track 14-1Innovative strategies for cost-efficient trials
- Track 14-2Strategies for financial forecasting and budgeting
- Track 14-3Working with sites: Budgeting and payments
- Track 14-4Strategies for efficient negotiation and contracting
- Track 14-5Contracting and resource allocation
- Track 14-6Phamracoeconomics
- Track 15-1Effective tracking, managing and distributing clinical supplies
- Track 15-2Tech tools for tracking and tracing clinical supplies
- Track 15-3Direct-to-Patient distribution: Meeting the patient’s needs
- Track 15-4Patient centered clinical trial material design and delivery
- Track 15-5Patient centricity and clinical supply
- Track 15-6Innovative supply management strategies
- Track 15-7Considerations for managing clinical supplies
- Track 16-1Trends in the globalization of clinical trials
- Track 16-2Strategies for successful globalization of clinical trials
- Track 16-3Ethical and scientific implications
- Track 16-4Globalization of drug development
- Track 16-5USA Clinical Trials
- Track 16-6Europe Clinical Trials
- Track 16-7UK Clinical Trials
- Track 16-8Canada Clinical Trials
- Track 16-9Japan Clinical Trials
- Track 16-10Asia Clinical Trials
- Track 17-1Cancer and HIV/AIDS case reports
- Track 17-2Breast cancer case reports
- Track 17-3Diabetes case reports
- Track 17-4Dermatology, gastroenterology, Nephrology, pulmonology and urology case reports
- Track 17-5Case reports in neurology, ophthalmology, obstetrics and gynecology
- Track 18-1Compliance and regulatory requirements in clinical research
- Track 18-2Good clinical practice
- Track 18-3Bridging regulations to Real-World health care
- Track 18-4Navigating the clinical trials regulatory landscape
- Track 18-5New regulatory flexibility driving positive industry change
- Track 18-6Regulatory implications and opportunities with new technologies
- Track 18-7Value of ethics in clinical research
- Track 18-8Ethics & Human subject protection
- Track 18-9Ethics and patient’s rights
- Track 18-10Bioethics: Case studies and ethical regulatory guidelines
- Track 18-11Ethical challenges in cancer clinical trials
- Track 19-1Priorities and needs of PV at different stages of a product life-cycle
- Track 19-2Challenges and opportunities in PV lifecycle management
- Track 19-3IT solutions for pharmacovigilance
- Track 19-4Safety surveillance and risk management lifecycle
- Track 19-5Innovations and trends in clinical drug safety